Description: Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Home Page: www.genmab.com
Carl Jacobsens Vej 30
Copenhagen,
2500
Denmark
Phone:
45 70 20 27 28
Officers
| Name | Title |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
| Mr. Anthony Pagano CPA | Executive VP & CFO |
| Ms. Birgitte Stephensen M.Sc. | Executive VP & Chief Legal Officer |
| Mr. Christopher Cozic | Executive VP & Chief People Officer |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
| Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director |
| Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
| Dr. Tahamtan Ahmadi | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director |
| Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 14.7929 |
|---|---|
| Trailing PE: | 21.2371 |
| Price-to-Book MRQ: | 3.0574 |
| Price-to-Sales TTM: | 0.6659 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2635 |